Eberhard Schneider

USPTO Granted Patents = 17 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

8 out of 16,338

E.i. Dupont De Nemours and Company

patents

4 out of 28

Ra Pharmaceuticals, Inc.

Baxter International Inc.

Takeda Pharmaceutical Company Limited

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11001613 - TFPI inhibitors and methods of use (2021-05-11),

2. 10272132 - Peptide and peptidomimetic inhibitors (2019-04-30),

3. 9999650 - Peptide and peptidomimetic inhibitors (2018-06-19),

4. 9777051 - TFPI inhibitors and methods of use (2017-10-03),

5. 9644004 - Peptide and peptidomimetic inhibitors (2017-05-09),

6. 9238676 - Peptide and peptidomimetic inhibitors (2016-01-19),

7. 9145445 - Methods for purifying pertussis toxin and peptides useful therefor (2015-09-29),

8. 8466108 - TFPI inhibitors and methods of use (2013-06-18),

9. 8455614 - PMMA binding peptides (2013-06-04),

10. 8404214 - PMMA binding peptides (2013-03-26),

11. 8389675 - PMMA binding peptides (2013-03-05),

12. 8378065 - PMMA binding peptides (2013-02-19),

13. 8299210 - Methods for purifying pertussis toxin and peptides useful therefor (2012-10-30),

14. 8287845 - Hair-binding peptides (2012-10-16),

15. 8263737 - PMMA binding peptides (2012-09-11),

Title: **Eberhard Schneider: Innovator in Blood Coagulation Therapeutics**

Introduction

Eberhard Schneider, a prolific inventor based in Denkte, Germany, has made significant contributions to the field of biomedical research, particularly in blood coagulation. With a remarkable portfolio that includes 17 patents, his innovations are targeted towards enhancing medical treatments for coagulation disorders.

Latest Patents

Among Schneider's latest inventions are two notable patents that focus on Tissue Factor Pathway Inhibitors (TFPI) and plasma kallikrein. His patent on TFPI inhibitors provides peptides designed to bind to Tissue Factor Pathway Inhibitor, offering unique solutions for enhancing thrombin formation in clotting factor-deficient subjects. These peptides aim to increase blood clot formation and serve as potential therapies for various blood coagulation disorders. Furthermore, his invention related to peptide and peptidomimetic inhibitors presents antagonists of plasma kallikrein, extending the therapeutic applications of these inhibitors.

Career Highlights

Eberhard Schneider has had an impressive career, having worked with esteemed organizations such as E.I. du Pont de Nemours and Company and Ra Pharmaceuticals, Inc. These experiences have placed him at the forefront of innovation in his field, allowing him to develop groundbreaking therapies that address critical healthcare challenges.

Collaborations

Throughout his career, Schneider has collaborated with notable professionals, including his coworkers Peter Wagner and Gregor Schurmann. These partnerships have undoubtedly facilitated his inventive endeavors, fostering a collaborative environment in the pursuit of advancements in medical treatments.

Conclusion

Eberhard Schneider stands out as a distinguished inventor whose work has significantly impacted the realm of blood coagulation therapy. His numerous patents reflect a deep commitment to enhancing medical outcomes for patients with coagulation disorders. Through his innovative ideas and collaboration with industry experts, Schneider continues to push the boundaries of medical science, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.